RoslinCT continues its growth plans by expanding its operations at Edinburgh Technopole
RoslinCT – a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole. The additional space will include fully...Pandemic Science Hub to develop better drugs to fight lung disease
A new multi-million pound research programme to develop treatments for lung infections such as Covid-19 and future pandemics has been announced at the University of Edinburgh with support from a significant donation by Baillie Gifford. The Baillie Gifford Pandemic...GHO Capital invests in RoslinCT, a leading cell therapy CDMO
RoslinCT, a leading Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, announces investment from Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare....
BioQuarter opens bidding for private sector partner for £1bn transformation project
Edinburgh BioQuarter has formally launched its public procurement process for a private sector partner. The opportunity to create a £1billion (estimated gross development value) health innovation district which will create jobs, homes, and a community for thousands of...Edinburgh BioQuarter and Edinburgh Innovations announce Progress innovation in a collaborative ecosystem webinar
Progress innovation in a collaborative ecosystem Webinar 13:00-14:00 BST, 31 August 2021 Hosted jointly by Edinburgh BioQuarter and Edinburgh Innovations, the webinar will explore how new medical treatments are progressed from bench to bedside at BioQuarter, and the...
